Pathology: mML - L1 - BRAF wild;
| mML - L1 - BRAF wild | ||||
| IMspire-170, 2020 | CheckMate 066, 2015 | CheckMate 069 (BRAF wild type), 2015 | ||
| atezolizumab plus cometinib | 1 | T1 | ||
| nivolumab alone | 1 | T1 | ||
| nivolumab plus ipilimumab | 1 | T1 | ||
| pembrolizumab alone | 0 | T0 | ||
| dacarbazine | 0 | T0 | ||
| ipilimumab alone | 0 | T0 | ||